Thursday, 15 October 2026European Markets

DGB GROUP N.V. Stock Went Down By Over 20% In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of DGB GROUP N.V. (AEX-Index: DGB.AS) dropped by a staggering 20.51% in 10 sessions from €0.78 to €0.62 at 14:07 EST on Tuesday, following the last session's upward trend. AEX-Index is rising 0.71% to €763.85, following the last session's downward trend.

DGB GROUP N.V.'s last close was €0.62, 48% under its 52-week high of €1.20.

About DGB GROUP N.V.

DGB Group N.V. invests in, develops, and manages biodiversity and carbon offset projects for businesses and governments in the Netherlands and internationally. The company provides nature-based solutions, as well as focuses on nature conservation activities. It is also involved in the trees breeding and planting business. The company was formerly known as Verenigde Nederlandse Compagnie N.V. and changed its name to DGB Group N.V. in January 2018. DGB Group N.V. was founded in 1957 is based in Rotterdam, the Netherlands.

Earnings Per Share

As for profitability, DGB GROUP N.V. has a trailing twelve months EPS of €-0.1.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -19%.

Moving Average

DGB GROUP N.V.'s value is way under its 50-day moving average of €0.78 and way below its 200-day moving average of €0.95.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, DGB GROUP N.V.'s stock is considered to be overbought (>=80).

Yearly Top and Bottom Value

DGB GROUP N.V.'s stock is valued at €0.62 at 14:07 EST, way below its 52-week high of €1.20 and way above its 52-week low of €0.55.

More news about DGB GROUP N.V. (DGB.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com